Navigation Links
FDA approves ULORIC (febuxostat) for the chronic management of hyperuricemia in patients with gout
Date:2/18/2009

Deerfield, Ill., and Osaka, Japan, February 13, 2009 Takeda Pharmaceutical Company Limited and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc., announced today that the United States Food and Drug Administration (FDA) has approved ULORIC (febuxostat) 40 mg and 80 mg for the chronic management of hyperuricemia in patients with gout. This once-daily, oral medication is the first new treatment option in more than 40 years for the more than five million patients who have hyperuricemia associated with gout. ULORIC was discovered by Teijin Pharma Limited (Teijin Pharma) of Tokyo and licensed to Takeda for the U.S. market.

"The approval of ULORIC offers clinicians and their patients who have hyperuricemia associated with gout a new treatment option that helps prevent uric acid production," said Nancy Joseph-Ridge, M.D., president, Takeda Global Research & Development Center, Inc., U.S. "In the years that we've dedicated to studying patients who have gout, I know that many patients go to their doctor during a flare not understanding that gout is a chronic disease that needs to be managed on a long-term, daily basis."

Experts recognize that a goal in the treatment of chronic gout is the reduction and maintenance of serum uric acid levels of less than 6 mg/dL. ULORIC, a xanthine oxidase inhibitor, effectively lowers levels of serum uric acid in patients with hyperuricemia associated with gout. It was studied and evaluated in multiple clinical trials involving more than 4,000 subjects, in some for up to five years.

The largest, pivotal, phase 3 clinical trial, CONFIRMS, demonstrated that ULORIC 80 mg was superior to ULORIC 40 mg and allopurinol 300/200 mg (67 percent, 45 percent and 42 percent, respectively) at achieving the primary end point of serum uric acid less than 6.0 mg/dL at the final visit (both p<0.001).

ULORIC has an established safety profile with no dose adjustments required in patients with mild
'/>"/>

Contact: Amy Losak
amy.losak@ketchum.com
917-865-6688
Takeda Pharmaceuticals North America
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. FDA Approves First Anti-Psychotic for Kids
2. FDA Approves New Roche West Nile Virus Blood Screening Test
3. FDA Approves Osteoporosis Drug to Cut Breast Cancer Risk
4. FDA Approves LEVAQUIN(R) Short-Course Therapy for Treatment of Complicated Urinary Tract Infections and Acute Pyelonephritis
5. FDA Approves SOMA(R) (carisoprodol) 250 mg
6. FDA Approves Expanded Label for FluMist(R) to Include Children Two to Five Years of Age
7. FDA approves expanded label for FluMist (influenza virus vaccine live, intranasal) to include childr
8. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
9. ABIH Approves Certification Credit for SSPC Training Courses
10. FDA Approves REALIZE(TM) Adjustable Gastric Band for Morbid Obesity
11. FDA Approves New Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... B. E. Smith, the only full-service leadership solutions ... to lead a national chief executive officer ... Sioux Falls, S.D. The top executive search firm in ... more than 900 healthcare executives into organizations. , ... and nationally recognized leader in patient-centered care. It is ...
(Date:9/2/2014)... Niagara Falls, New York (PRWEB) September 02, 2014 ... scabies ?” This is the question that millions of ... challenge among health care providers, patients and their families ... lead to misdiagnosis due to its distinct similarities to ... atopic dermatitis, impetigo, bed bug bites, eczema, varicella and ...
(Date:9/2/2014)... September 02, 2014 QueenBeeTickets.com , home ... is now stocking James Taylor concert tickets for the singer’s ... U.S. cities from November 1 to the 19th. , James ... again on the 4th of the month. General onsales to ... are all set to obtain seats for one of his ...
(Date:9/2/2014)... September 02, 2014 ZAMST, a leader ... endorsement deal with professional baseball star Nolan Arenado ... best young baseball players, Arenado will be working with ... specific product category. , Arenado was selected by ... #59 overall. In 2013, Arenado was awarded the Gold ...
(Date:9/2/2014)... At the 50th Annual Mr. Olympia Fitness ... exhibitor at the Las Vegas Convention Center South Hall, ... Booth #374 Sept 19th and 20th 10am-5PM. , ... exercise, diet and supplementation. They pride themselves on creating ... for all Prosupps customers to reach their personal health ...
Breaking Medicine News(10 mins):Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 2Health News:Sioux Falls Specialty Hospital Retains B. E. Smith to Recruit New CEO 3Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 2Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 3Health News:New Breakthrough Formula - Dr. Scabies® : The New Industry Standard Treatment for Scabies to Fight the Scabies Breakout 4Health News:James Taylor Presale Tickets for 10 November Concerts On Sale Today From Trusted Provider QueenBeeTickets.com 2Health News:Gold Glove Baseball Star Nolan Arenado Signs With Zamst 2Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2
... Journal has just come out. In it,s 23rd year it helps new ... progress. It is both a keepsake, and a lifesaver in an emergency. ... inception. A diaper bag must. , ... Fountain Valley, CA (PRWEB) January ...
... Robert L. Peck discusses connections between the mind and body, hormone ... aware of the effects of hormones and how many of the ... ... Lebanon, CT (PRWEB) January 21, 2009 -- ,Controlling Your Hormones, ...
... CINCINNATI After identifying an apparent population of cancer ... herpes virus to block tumor formation in mice by ... 21 by PLoS (Public Library of Science) One ... Center adds to a growing body of evidence suggesting ...
... came into effect, granting children 12 years and older ... the right to access condoms. But current policies ... give out condomspolicies that two researchers, writing in this ... health of the country,s youth. , Juliana Han (Harvard ...
... , ... (PRWEB) January 20, 2009 -- It has come ... confusion as to the intentions of its iPhone application previously for ... to its attention-grabbing name, and the unfortunate media confusion and common ...
... health and exercise programs have positive outcomes despite having ... exercise they do outside of school, say Cochrane Researchers ... physical activity programs in schools. , The research shows ... and reduced the time spent watching television. Programs also ...
Cached Medicine News:Health News:Pocket Reference Journals Releases Latest Edition of "All About Me" Leading Children's Immunization Journal for New Moms 2Health News:Pocket Reference Journals Releases Latest Edition of "All About Me" Leading Children's Immunization Journal for New Moms 3Health News:Newly Released Book by Retired Scientist Links Self-Control of Hormones to Perfecting One's Life 2Health News:Newly Released Book by Retired Scientist Links Self-Control of Hormones to Perfecting One's Life 3Health News:Engineered virus targets and kills apparent cancer stem cells in neuroblastoma 2Health News:Engineered virus targets and kills apparent cancer stem cells in neuroblastoma 3Health News:South African policy on adolescents' rights to access condoms is causing confusion 2Health News:Teen Torture iPhone App Discontinued Due to Public Alarm 2Health News:Teen Torture iPhone App Discontinued Due to Public Alarm 3Health News:School-based physical activity: Has benefits even if it doesn't help lose weight 2
(Date:9/2/2014)... FRANCISCO, Calif. , Sept. 2, 2014   Veracyte, ... Bonnie H. Anderson , president and chief executive officer, ... Morgan Stanley Global Healthcare Unplugged Conference 2014 on Monday, September ... York . The live audio webcast and ... http://investor.veracyte.com . Please connect to the website at least ...
(Date:9/2/2014)... , Switzerland , September 2, ... ISO 13485 accreditation, Sophia Genetics has become the first ... use of a Next Generation Sequencing (NGS) bioinformatic ... represents an important step in raising the standards ... brings Sophia Genetics, world-leading Data Driven Medicine platform ...
(Date:9/2/2014)... , Sept. 2, 2014  For over a decade SafeMinds ... link between vaccines and autism. But at least for one ... In a statement , William Thompson , Ph.D. ... linking the MMR vaccine to an increased risk of autism ... the same data suggests that African American males have a ...
Breaking Medicine Technology:Veracyte to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2014 2Sophia Genetics Becomes the First European Company to Obtain CE-IVD Mark for Clinical use of Next Generation Sequencing Bioinformatics Pipeline for Routine Genetic Testing 2CDC vaccine scientist admits wrongdoing. 2CDC vaccine scientist admits wrongdoing. 3
... ... that a new market research report is available in ... A Worldwide Market Review , http://www.reportlinker.com/p0164283/Decubitus-Ulcer-Treatment-Products---A-Worldwide-Market-Review.html ... damage caused by constant pressure of the patient,s bodyweight. ...
... , KING OF PRUSSIA, Pa., Nov. 30 ... Phase I study of CPSI-2364, its orally active, small-molecule inhibitor ... Results of the safety and tolerability dose escalation study in ... clinical testing. , All 30 enrolled subjects completed ...
Cached Medicine Technology:Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 2Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 3Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 4Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 5Reportlinker Adds Decubitus Ulcer Treatment Products - A Worldwide Market Review 6Cytokine PharmaSciences Completes Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364 2
Enzyme Immunoassay of von Willebrand Factor Antigenby ELISA Method, 96 tests....
Enzyme Immunoassay of Factor IX Antigen by ELISA Method, 96 tests....
Enzyme Immunoassay of Platelet Factor 4 Antigen by ELISA Method, 96 tests....
HbA1c / HbCalibrator...
Medicine Products: